Author:
Mejía-Vilet Juan M.,Ayoub Isabelle
Abstract
Glucocorticoids therapy has greatly improved the outcome of lupus nephritis patients. Since their discovery, their adverse effects have counterbalanced their beneficial anti-inflammatory effects. Glucocorticoids exert their effects through both genomic and non-genomic pathways. Differential activation of these pathways is clinically relevant in terms of benefit and adverse effects. Ongoing aims in lupus nephritis treatment development focus on a better use of glucocorticoids combined with immunosuppressant drugs and biologics. Newer regimens aim to decrease the peak glucocorticoid dose, allow a rapid glucocorticoid tapering, and intend to control disease activity with a lower cumulative glucocorticoid exposure. In this review we discuss the mechanisms, adverse effects and recent strategies to limit glucocorticoid exposure without compromising treatment efficacy.
Reference118 articles.
1. Adrenocortical hormone in arthritis : preliminary report;Hench;Ann Rheum Dis.,1949
2. The history of cortisone discovery and development;Burns;Rheum Dis Clin North Am.,2016
3. A Comparison of cortisone and prednisone in treatment of rheumatoid arthritis;Cameron;Br Med J.,1957
4. Lupus nephritis: an historical perspective 1968-1998;Cameron;J Nephrol,1999
5. The natural history of the renal manifestations of systemic lupus erythematosus. 1964.;Pollak;J Am Soc Nephrol,1997
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献